Redeye comments on the cancellation of the Pollen Street agreement, which the company signed in Q3 l...
Q2 report Friday, 18 July at 12:00 CET '25e-'27e adj.
Redeye comments on SSH Communications' announcement that it intends to enter a strategic partnership...
Redeye comments on W5 Solutions announcement of a directed share issue totalling cSEK104m which stre...
Redeye provides commentary on BeammWave's recent developments.
Organic growth could remain close to zero for H1 2025E y/y, but acquisitions should at least offer 6...
Nettoomsättningen uppgick till 45,3 MSEK (43,7) i det fjärde kvartalet (feb-apr) i Vuxen Groups brut...
Redeye shares its preview of BONESUPPORT’s Q2 2025 results, due July 15.
Redeye comments on the changes in CLS’s Board of Directors.
Redeye comments on OncoZenge’s announcement that SAFE has approved its SEK30.
Redeye updates its base case of Synact following the directed share issue and new programme in polym...
Redeye revises its financial forecast and valuation of Polygiene following the change of lead analys...
Synthetic MR:s förseningar i lanseringen av SyMRI 3D har lett till ett svagt första kvartal 2025, me...
Q2e: -4.5% organic sales growth, 9% adj. EBITA margin Expect continued caution in Sweden Trading at ...
Redeye comments on IRLAB’s announcement of a guaranteed SEK 136m rights issue aimed at advancing its...
Nettoomsättningen för det första kvartalet uppgick till 4,6 (3,5) miljoner kronor.
Administer announced that it intends to acquire the financial, payroll and software services busines...
Redeye thinks the phase II study is now on track, with the last patient recruited and preliminary re...
Redeye comments on today’s mandatory offer from Arise’s largest shareholder, the CA Group.
Redsense växer stabilt med stigande omsättning och förbereder lansering av Clamp i Storbritannien.
